Risk of CVD in patients with VT, adjusted for thrombophilia
| Subjects . | Individuals, n . | Observation-years . | Events, n . | Incidence rate per 1000 py (95% CI) . | Adjusted HR*(95% CI) . | Adjusted HR†(95% CI) . | Adjusted HR‡(95% CI) . | Adjusted HR§(95% CI) . |
|---|---|---|---|---|---|---|---|---|
| RDD controls | 2638 | 10 166 | 16 | 1.6 (0.9-2.6) | Reference | Reference | Reference | Reference |
| Patients | 4480 | 22 423 | 72 | 3.2 (2.5-4.0) | 2.2 (1.2-4.2) | 1.8 (0.9-3.6) | 1.9 (0.8-4.4) | 1.8 (0.8-4.3) |
| DVT | 2635 | 13 022 | 44 | 3.4 (2.5-4.5) | 2.4 (1.2-4.8) | 2.0 (0.9-4.3) | 1.9 (0.8-4.7) | 1.8 (0.7-4.6) |
| PE ± DVT | 1845 | 9402 | 28 | 3.0 (2.0-4.3) | 2.0 (1.0-4.3) | 1.6 (0.7-3.6) | 1.9 (0.7-5.3) | 1.8 (0.6-4.9) |
| Partner controls | 2926 | 16 402 | 36 | 2.2 (1.5-3.0) | Reference | Reference | Reference | Reference |
| Patients | 4480 | 22 423 | 72 | 3.2 (2.5-4.0) | 1.5 (1.0-2.4) | 1.4 (0.9-2.3) | 1.4 (0.7-2.6) | 1.3 (0.7-2.5) |
| DVT | 2635 | 13 022 | 44 | 3.4 (2.5-4.5) | 1.6 (1.0-2.7) | 1.5 (0.9-2.6) | 1.4 (0.7-2.9) | 1.3 (0.6-2.6) |
| PE ± DVT | 1845 | 9402 | 28 | 3.0 (2.0-4.3) | 1.4 (0.8-2.5) | 1.3 (0.7-2.3) | 1.4 (0.7-3.2) | 1.4 (0.6-3.2) |
| Subjects . | Individuals, n . | Observation-years . | Events, n . | Incidence rate per 1000 py (95% CI) . | Adjusted HR*(95% CI) . | Adjusted HR†(95% CI) . | Adjusted HR‡(95% CI) . | Adjusted HR§(95% CI) . |
|---|---|---|---|---|---|---|---|---|
| RDD controls | 2638 | 10 166 | 16 | 1.6 (0.9-2.6) | Reference | Reference | Reference | Reference |
| Patients | 4480 | 22 423 | 72 | 3.2 (2.5-4.0) | 2.2 (1.2-4.2) | 1.8 (0.9-3.6) | 1.9 (0.8-4.4) | 1.8 (0.8-4.3) |
| DVT | 2635 | 13 022 | 44 | 3.4 (2.5-4.5) | 2.4 (1.2-4.8) | 2.0 (0.9-4.3) | 1.9 (0.8-4.7) | 1.8 (0.7-4.6) |
| PE ± DVT | 1845 | 9402 | 28 | 3.0 (2.0-4.3) | 2.0 (1.0-4.3) | 1.6 (0.7-3.6) | 1.9 (0.7-5.3) | 1.8 (0.6-4.9) |
| Partner controls | 2926 | 16 402 | 36 | 2.2 (1.5-3.0) | Reference | Reference | Reference | Reference |
| Patients | 4480 | 22 423 | 72 | 3.2 (2.5-4.0) | 1.5 (1.0-2.4) | 1.4 (0.9-2.3) | 1.4 (0.7-2.6) | 1.3 (0.7-2.5) |
| DVT | 2635 | 13 022 | 44 | 3.4 (2.5-4.5) | 1.6 (1.0-2.7) | 1.5 (0.9-2.6) | 1.4 (0.7-2.9) | 1.3 (0.6-2.6) |
| PE ± DVT | 1845 | 9402 | 28 | 3.0 (2.0-4.3) | 1.4 (0.8-2.5) | 1.3 (0.7-2.3) | 1.4 (0.7-3.2) | 1.4 (0.6-3.2) |
PE, pulmonary embolism; py, person-years.
Adjusted for anticoagulation therapy, age, sex, BMI, smoking, chronic disease (defined as liver disease, kidney disease, multiple sclerosis or rheumatoid arthritis), and malignancy.
Adjusted for anticoagulation therapy, age, sex, BMI, smoking, chronic disease, malignancy, factor V Leiden, prothrombin G20210A, and blood group non-O.
Adjusted for anticoagulation therapy, age, sex, BMI, smoking, chronic disease, malignancy, factor VIII, fibrinogen, and C-reactive protein.
Fully adjusted for all abovementioned factors.